Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2019

Revenue Recognition

Schedule of disaggregation of revenue by test families

	Three months ended				Six months ended
	June 30,				June 30,
	2019		2018		2019		2018
(Amounts in thousands)
Sales of genetic tests
Panorama NIPT	$	36,467	$	35,715	$	73,713	$	68,982
HCS		24,286		21,421		47,035		39,683
Other genetic tests		4,346		3,217		7,715		5,957
Product revenues		65,099		60,353		128,463		114,622
Licensing and other
Constellation		1,312		1,293		2,644		2,598
Qiagen		527		94		675		5,594
BGI		5,018		—		5,018		—
Other		2,399		1,329		4,379		2,595
Licensing and other revenues		9,256		2,716		12,716		10,787
Total revenues	$	74,355	$	63,069	$	141,179	$	125,409

Schedule of disaggregation of revenue by payer types

	Three months ended				Six months ended
	June 30,				June 30,
	2019		2018		2019		2018
(Amounts in thousands)
Insurance carriers	$	50,777	$	48,321	$	100,978	$	92,463
Laboratory partners		15,132		10,132		25,155		25,020
Patients		8,446		4,616		15,046		7,926
Total revenues	$	74,355	$	63,069	$	141,179	$	125,409

Schedule of total revenue by geographic area

	Three months ended				Six months ended
	June 30,				June 30,
	2019		2018		2019		2018
(Amounts in thousands)
United States	$	62,393	$	56,631	$	122,676	$	106,995
Americas, excluding U.S.		767		847		1,585		1,697
Europe, Middle East, India, Africa		4,318		3,756		8,322		13,078
Other		6,877		1,835		8,596		3,639
Total revenues	$	74,355	$	63,069	$	141,179	$	125,409

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at		Balance at
	June 30,		December 31,
(Amounts in thousands)	2019		2018
Assets:
Accounts receivable	$	62,974	$	62,223
Liabilities:
Deferred revenue, current portion	$	19,154	$	4,131
Deferred revenue, long-term portion		60,527		40,058
Total deferred revenues	$	79,681	$	44,189

Schedule of changes in the balance of deferred revenues

	Deferred
	Revenues
	(in thousands)
Balance at December 31, 2018	$	44,189
Increase in deferred revenues		45,524
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(733)
Revenue recognized from performance obligations satisfied within the same period		(9,299)
Balance at June 30, 2019	$	79,681

Schedule of current and long-term portions of deferred revenues

Deferred Revenues	Current		Long-term		Total
BGI agreement		15,000		19,982		34,982
Qiagen agreement		1,963		36,568		38,531
Other deferred revenues	$	2,191	$	3,977	$	6,168
Balance at June 30, 2019	$	19,154	$	60,527	$	79,681